Libtayo + chemo approved by EC for first-line treatment of advanced PD-L1-positive NSCLC

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Specific sequences of chemotherapy, targeted therapy, and immunotherapy yielded significantly different results, according to a study that utilized simulation models and real-world data to predict outcomes under different sequencing scenarios.

July 18, 2025

Vol.51 No.28

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Drugs & Targets

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Meitheal Pharmaceuticals Inc. on May 29 announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd., paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane, in the U.S.

June 06, 2025

Vol.51 No.22

Libtayo + chemo approved by EC for first-line treatment of advanced PD-L1-positive NSCLC

YOU MAY BE INTERESTED IN

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Sequences of cancer treatments affect patient outcomes and healthcare costs, UC Irvine-led study shows

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S.

Renew today!

Subscriber content

Never miss an issue!

Login